Statin Use in Relation to Prostate Cancer Outcomes in a Population‐based Patient Cohort Study. Issue 11 (30th April 2013)

• Record Type: Journal Article
• Authors: Geybels, Milan S.; Wright, Jonathan L.; Holt, Sarah K.; Kolb, Suzanne; Feng, Ziding; Stanford, Janet L.
• Is Part Of: Prostate. Volume 73:Issue 11(2013)
• Page Start: 1214
• Page End: 1222
• Publication Date: 2013-04-30
• Subjects: Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.22671
• Languages: English
• ISSNs: 0270-4137

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pros22671-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>We investigated associations between statin use begun before prostate cancer (PCa) diagnosis and PCa recurrence/progression and PCa‐specific mortality (PCSM) in a prospective, population‐based cohort study.</p> </sec> <sec id="pros22671-sec-0002" sec-type="section"> <title>METHODS</title> <p>The analysis included 1, 001 PCa patients diagnosed in 2002–2005 in King County, Washington. Statin use was assessed at the time of diagnosis using a detailed in‐person interview. Prostate cancer recurrence/progression events and cause‐specific survival were ascertained from a follow‐up survey and the SEER registry. Multivariable competing risk and Cox proportional hazards regression models were used to assess the risk of PCa outcomes according to categories of statin use.</p> </sec> <sec id="pros22671-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Of the 1, 001 PCa patients in our study, 289 men were ever users of statin drugs. During follow‐up, we identified 151 PCa recurrence/progression events and 123 total deaths, including 39 PCa‐specific deaths. In unadjusted analysis, the risk of PCSM was significantly lower for statin users compared to non‐users (1% vs. 5% at 10 years; <italic>P</italic> < 0.01). In multivariable analysis, the adjusted hazard ratio of PCSM for statin users versus non‐users was 0.19 (95% CI: 0.06, 0.56). Statin use was not associated with overall PCa recurrence/progression and other‐cause mortality.</p> </sec> <sec id="pros22671-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Statin use begun before PCa diagnosis was unrelated to PCa recurrence/progression but was associated with a decrease in risk of PCSM. Prostate 73: 1214–1222, 2013. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>